Pfizer gets U.S. approval for $225,000 a year heart drug

The U.S. Food and Drug Administration on Monday approved Pfizer Inc's oral drug, tafamidis, to treat a rare and fatal heart disease called transthyretin amyloid cardiomyopathy, the U.S drugmaker said.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news